Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 62Prostatic Neoplasms 35Kidney Neoplasms 18Carcinoma, Transitional Cell 17Melanoma 15Urinary Bladder Neoplasms 14Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Clear-cell metastatic renal cell carcinoma 11Colorectal Neoplasms 9Neoplasms 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Pancreatic Neoplasms 5Urogenital Neoplasms 4Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Urethral Neoplasms 3Penile Neoplasms 3Neuroblastoma 3Liver Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Ureteral Neoplasms 2

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Ipilimumab × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡